Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human immunodeficiency virus (HIV) prevention, scheduled for January 2026.

Interviews in Pakistan highlight what people with HIV want from long-acting injectable antiretroviral therapy and what may ...

Patients with HIV who were more impacted by health disparities were less likely to find long-acting injectable antiretroviral therapy appealing. LAI-ART is a novel tool that can be used to treat PWH ...

An injectable antiretroviral drug: Long-acting Cabotegravir and rilpivirine (LA-CAB/RPV) is effective in treating HIV, New Vision Online has learnt. According to the CARES study, the first trial ...

Aadia Rana, M.D., professor of medicine in the Division of Infectious Diseases at the University of Alabama at Birmingham, senior scientist with the UAB Center for AIDS Research and study chair for ...

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

Antiretroviral therapy (ART) intramuscularly administered may have the same effectiveness as current oral treatments. This is the main conclusion of the Phase II clinical trial carried out by 50 ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UC San Francisco has found. The strategy could also help stop the spread ...

Jennifer Cocohoba, PharmD, MAS, AAHIVP, University of California, San Francisco, School of Pharmacy, discusses the benefits of pharmacy-administered long-acting injectable antiretroviral therapy for ...